Among them, plitidepsin was approved in Australia for combined treatment of relapsed/refractory multiple myeloma with dexamethasone [41], thus providing initial proof of principle that eEF1A inhibitors can achieve the desired therapeutic efficacy with safety. The gene discussed is EEF1A1; the disease is plasma cell myeloma.